Vaginal ring contraception

Contraception

Volumn 83, Issue 2, 2011, Pages 107-115

  Kerns, Jennifer ^a   Darney, Philip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Combined hormonal contraception; Combined vaginal ring; Vaginal contraception; Vaginal ring

Indexed keywords

ETHINYLESTRADIOL PLUS ETONOGESTREL;

ARTICLE; BREAKTHROUGH BLEEDING; DYSMENORRHEA; ENDOMETRIOSIS; HORMONAL CONTRACEPTION; HUMAN; HYPERANDROGENISM; LACTATION; LEUKORRHEA; MENORRHAGIA; MENSTRUAL CYCLE; OVARY POLYCYSTIC DISEASE; OVULATION INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SATISFACTION; VAGINA EPITHELIUM; VAGINA RING; VAGINITIS;

EID: 78651420923     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2010.07.008     Document Type: Review

References (79)

1. World Contraceptive Use United Nations Department of Economic and Social Affairs 2009 Population Division New York 2009
2. Singh S., Darroch J., Vlassoff M., and Nadeau J. Adding it up: the benefits of investing in sexual and reproductive health care 2004 The Alan Guttmacher Institute and UNFPA Washington, DC
3. Blackburn R, Cunkelman A, Zlidar V. Oral contraceptives - an update. Popul Rep A Oral Contracept 2000;28:1-16, 25-32.
4. Hatcher R., Trussell J., and Stewart F. Contraceptive technology 18 ed. 2004 Ardent Media, Inc. New York
5. Rosenberg M., Waugh M., and Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives J Reprod Med 40 1995 355 360
6. Davis A., Godwin A., Lippman J., Olson W., and Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding Obstet Gynecol 96 2000 913 920
7. Larsson G., Milsom I., Lindstedt G., and Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status Contraception 46 1992 327 334
8. Milsom I., Sundell G., and Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea Contraception 42 1990 497 506
9. Bronson R. Oral contraception: mechanism of action Clin Obstet Gynecol 24 1981 869 877
10. Vessey M., and Painter R. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study Br J Cancer 71 1995 1340 1342
11. Creasy G., Hall N., and Shangold G. Patient adherence with the contraceptive patch dosing schedule versus oral contraceptives Obstet Gynecol 60S 2000 95
12. Dieben T., Roumen F., and Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring Obstet Gynecol 100 2002 585 593
13. Timmer C., and Mulders T. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring Clin Pharmacokinet 39 2000 233 242
14. van den Heuvel M., van Bragt A., Alnabawy A., and Kaptein M. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive Contraception 72 2005 168 174
15. Mishell D.R., Talas M., Parlow A., and Moyer D. Contraception by means of a Silastic vaginal ring impregnated with medroxy progesterone acetate Am J Obstet Gynecol 107 1970 100 107
16. Johansson E., and Sitruk-Ware R. New delivery systems in contraception: vaginal rings Am J Obstet Gynecol 190 2004 S54 S59
17. Ahren T., Victor A., Lithell H., and Johansson E. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring: I. Carbohydrate metabolism and liver function Contraception 24 1981 415 427 (Pubitemid 12239511)
18. Roumen F., Apter D., Mulders T., and Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol Hum Reprod 16 2001 469 475
19. Roumen F., and Dieben T. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of the contraceptive vaginal ring and an oral contraceptive Fertil Steril 85 2006 57 62
20. Killick S. Complete and robust ovulation inhibition with NuvaRing Eur J Contracept Reprod Health Care 7 2002 S13 S18
21. Duijkers I., Klipping C., Verhoeven C., and Dieben T. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study Hum Reprod 19 2004 2668 2673 (Pubitemid 39481298)
22. Mulders T., and Dieben T. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition Fertil Steril 75 2001 865 870
23. Mulders T., Dieben T., and Bennink H. Ovarian function with a novel combined contraceptive vaginal ring Hum Reprod 17 2002 2594 2599
24. Trussell J. Contraceptive failure in the United States Contraception 70 2004 89 96
25. Ahrendt H.J., Nisand I., and Bastianelli C. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 mcg of ethinyl estradiol and 3 mg of drospirenone Contraception 74 2006 451 457
26. Oddsson K., Leifels-Fischer B., and de Melo N. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial Contraception 71 2005 176 182
27. Lopez L., Grimes D., Gallo M., and Schulz K. Skin patch and vaginal ring versus oral contraceptives for contraception Cochrane Database Syst Rev 3 2010 CD003552
28. Merki-Feld G., and Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: Cycle control and acceptability among women of all reproductive ages Eur J Contracept Reprod Health Care 12 2007 240 247
29. Schafer J., Osborne L., Davis A., and Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive Contraception 73 2006 488 492
30. Creinin M., Meyn L., and Borgatta L. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial Contraception 111 2008 267 277
31. Roumen F., op ten Berg M., and Hoomans E. The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands Eur J Contracept Reprod Health Care 11 2006 14 22
32. Sabatini R., and Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives Contraception 74 2006 220 223
33. Gilliam M., Neustadt A., Kozloski M., Mistretta S., Tilmon S., and Godfrey E. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial Obstet Gynecol 115 2010 503 510
34. Gallo M., Nanda K., Grimes D., Lopez L., and Schulz K. 20 μg versus >20 μg estrogen combined oral contraceptives for contraception Cochrane Database Syst Rev 1 2008 CD003989
35. Veres S., Miller L., and Burington B. A comparison between the vaginal ring and oral contraceptives Obstet Gynecol 104 2004 555 563
36. Bjarnadottir R., Tuppurainen M., and Killick S. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ ethinyl estradiol Am J Obstet Gynecol 186 2002 389 395
37. Verecellini P., Barbara G., Somigliana E., Bianchi S., Abbiati A., and Fedele L. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis Fertil Steril 93 2010 2150 2161
38. Westhoff C., Osborne L., Schafer J., and Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive Obstet Gynecol 106 2005 89 96
39. Oddsson K., Leifels-Fischer B., and Wiel-Masson D. Superior cycle control with a contraceptive vaginal ring mcg ethinylestradiol and 150 compared with an oral contraceptive containing 30 mcg levonorgestrel: a randomized trial Hum Reprod 20 2005 557 562
40. Milsom I., Lete I., and Bjertnaes A. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 μg ethinyl estradiol and 3 mg drospirenone Hum Reprod 21 2006 2304 2311
41. O'Connell K., Osborne L., and Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive Contraception 72 2005 323 327
42. Guida M., Di Spiezio Sardo A., and Bramante S. Effects of two types of hormonal contraception-oral versus intravaginal-on the sexual life of women and their partners Hum Reprod 20 2005 1100 1106
43. Nappi C., Di Spezio S., and Acunzo G. Effects of a low-dose and ultra-low-dose combine oral contraceptive on bone turnover and bone mineral density in young, fertile women: a prospective controlled randomized study Contraception 67 2003 355 359
44. Massaro M., Di Carlo C., Gargano V., Formisano C., Bifulco G., and Nappi C. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study Contraception 81 2010 209 214
45. Gaffield M., Curtis K., Mohllajee A., and Peterson H. Medical eligibility criteria for new contraceptive methods: combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant Contraception 73 2006 134 144
46. Khader Y., Rice J., John L., and Abueita O. Oral contraceptive use and the risk of myocardial infarction: a meta-analysis Contraception 68 2003 11 17
47. Schwingl P., Ory H., and Visness C. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States Am J Obstet Gynecol 180 1999 241 249
48. Donnan G., Fisher M., Macleod M., and Davis S. Stroke Lancet 371 2008 1612 1623
49. Schurks M., Rist P., Bigal M., Buring J., Lipton R., and Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis BMJ 339 2009 1010 1018
50. Carolei A., Marini C., De Matteis G. and the, Italian National Research Council Study Group on Stroke in the Young History of migraine and risk of cerebral ischaemia in young adults Lancet 347 1996 1503 1506
51. Curtis K., Chrisman C., and Peterson H. Contraception for women in selected circumstances Obstet Gynecol 99 2002 1100 1112
52. MacGregor E., and Guillebaud J. in conjunction with the clinical and scientific committee of the faculty of family planning and reproductive health care and the family planning association. Combined oral contraceptives, migraine and ischaemic stroke Br J Fam Plan 24 1998 55 60
53. Chang C., Donaghy M., and Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception BMJ 318 1999 13 18
54. Farley T., Collins J., and Schlesselman J. Hormonal contraception and risk of cardiovascular disease Contraception 57 1998 211 230
55. Lidegaard O., Lokkegaard E., Svendsen A., and Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study BMJ 339 2009 1 8
56. Kemmeren J., Algra A., and Grobbee D. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis BMJ 323 2001 131 134
57. Fleischer K., van Vliet H., Rosendaal F., Rosing J., Tchaikovski S., and Helmerhorst F. Effects of the contraceptive patch, the vaginal ring, and an oral contraceptive on APC resistance and SHBG: a cross-over study Thromb Res 123 2009 429 435
58. Jensen J., Burke A., Barnhart K., Tillotson C., Messerle-Forbes M., and Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis Contraception 78 2008 451 458
59. van Vliet H., Rosendaal F., Fleischer K., Rosing J., and Helmerhorst F. Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis Contraception 81 2010 88 89
60. Miller L., Verhoeven C., and Hout J. Extended regimens of the contraceptive vaginal ring Obstet Gynecol 106 2005 473 482
61. Barreiros F., Guazzelli C., Barbosa R., de Assis F., and de Araujo F. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects Contraception 81 2010 223 225
62. Guazzelli C., Barreiros F., Barbosa R., de Araujo F., and Moron A. Extended regimens of the contraceptive vaginal ring: cycle control Contraception 80 2009 430 435
63. Sulak P., Smith V., Coffee A., Witt I., Kuehl A., and Kuehl T. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring Obstet Gynecol 112 2008 563 571
64. Pasquali R., Gambineri A., and Anconetani B. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestogen treatment Clin Endocrinol 50 1999 517 527
65. Givens J., Andersen R., Wiser W., and Fish S. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive J Clin Endocrinol Metab 38 1974 727 735
66. Cullberg G., Hamberger L., Mattsson L., Mobacken H., and Samsioe G. Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome Acta Obstet Gynecol Scand 64 1985 195
67. Battaglia C., Genazzani A., Artini P., Salvatori M., Giulini S., and Volpe A. Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome Ultrasound Obstet Gynecol 12 1998 180 187 (Pubitemid 28474925)
68. Battaglia C., Mancini F., and Fabbri R. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized pilot study Fertil Steril 94 2010 1417 1425
69. Cagnacci A., Ferrari S., Tirelli A., Zanin R., and Volpe A. Route of administration of contraceptives containing desogestrel/etonogestrel and insulin sensitivity: a prospective randomized study Contraception 80 2009 34 39
70. Gupta N., Corrado S., and Goldstein M. Hormonal contraception for the adolescent Pediatr Rev 29 2008 386 396
71. Piccinino L, Mosher W. Trends in contraceptive use in the United States: 1982-1995. Fam Plan Persp 1998;30:4-10, 46.
72. Sivin I., Mishell D.R., and Alvarez F. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial Contraception 71 2005 122 129
73. Croxatto H., and Zepeda A. Transdermal contraceptive systems: innovative technology for the twenty-first century R. Sitruk-Ware, C. Bardin, Newer pharmacological agents, devices and delivery systems. Contraception 1992 M. Dekker Inc. New York 101 115
74. Brache V., Massai R., and Mishell D. Ovarian function during use of Nestorone® subdermal implants Contraception 61 2000 199 204
75. Massai R., Miranda P., and Valdes P. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women Contraception 60 1999 9 14
76. Caucus on New and Underused Reproductive Technologies Progesterone-only vaginal ring: a technical brief 2009 Reproductive Health Supplies Coalition Brussels, Belgium
77. Malcolm R., Woolfson A., Toner C., Morrow R., and McCullagh S. Long-term controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings J Antimicrob Chemother 56 2005 954 956
78. Woolfson A., Malcom R., Morrow R., Toner C., and McCullagh S. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC120 as an HIV microbicide Int J Pharm 325 2006 82 89
79. Saxena B., Han Y., and Fu D. Sustained release of microbicides by newly engineered vaginal rings AIDS 15 2009 917 922